Novocure Q2 2026: Revenue Ramps, EPS Sinks—TTFields Still Weathering the Path to Profitability
Lead: NVCR delivers a record revenue quarter, but the EPS remains negative
Novocure, ticker NVCR, reported second-quarter 2026 results that underscored a strong top line while the bottom line stayed in the red. The company posted roughly $183.6 million in total net revenues for the quarter, up about 16% year over year, as global active-patient growth accelerated across indications. On an earnings-per-share basis, the quarter produced a loss of $0.13 per share, a reminder that the business is still in the investment phase as it expands TTFields therapy to more markets. Analysts tracking NVCR will be weighing EPS consensus versus the actual print, and whether any earnings surprise materializes in subsequent quarters. Management did not issue a formal revenue forecast in this release, but the momentum raises the bar for how investors parse revenue trajectories versus the street’s expectations.
A quarter of geographic breadth and product momentum
The company highlighted robust revenue contributions from the U.S., Germany, France, and Japan, totaling $103.0 million, $23.3 million, $21.3 million, and $11.8 million, respectively, with other active markets contributing $18.2 million. Notably, Novocure recognized $2.8 million in net revenue from one-time benefits across the U.S., Germany, and France.
In product-speak, the quarter included $5.4 million of recognized revenue from Optune Lua and $1.6 million from Optune Pax, underscoring a bifurcated but growing mix of therapy options. In Greater China, revenue tied to the Zai Lab partnership reached $6.0 million, illustrating the company’s reliance on regional partnerships to extend TTFields adoption.
Margins, costs, and a one-time windfall
Gross margin expanded to 78% from 74% in the prior year, aided by a one-time $4.9 million tariff refund that helped the quarterly cost structure. Research, development, and clinical study expenses came in at $51.4 million, down about 8% year over year as some direct clinical-trial costs wound down.
Selling, general, and administrative costs rose modestly: Sales and marketing were $61.7 million (cited as a driver of the Optune Pax launch in the U.S. and Optune Lua in Japan), while G&A came in at $39.9 million, a 9% year-over-year decrease driven by lower share-based compensation. Net loss for the quarter was $15.7 million, or $0.13 per share, with Adjusted EBITDA of $10.8 million.
Strategic updates: regulatory wins and patient access
A key highlight was the CE Mark achievement for Optune Pax in the treatment of locally advanced pancreatic cancer, with Germany identified as the first EU market to launch. Novocure positioned this milestone as a stepping stone to broader EU and global expansion, aiming to bring TTFields therapy to more patients who could benefit.
By mid-year, the program had more than 280 active Pax patients on therapy as of June 30, 2026, offering early signals about the therapy’s real-world uptake as payer and clinical ecosystems adapt to TTFields technology.
What the quarter portends for NVCR and sector peers
The quarter’s narrative is balancing: strong top-line growth and patient momentum against the persistence of losses and near-term profitability challenges. The gross-margin uplift hints at favorable cost dynamics, yet the EPS print reminds investors that scale and mix must translate into sustainable cash generation to move the stock’s multiple. The Optune Pax and Lua launches, plus the China partnership revenue, suggest a diversification of mix that could become a meaningful earnings lever if market access and reimbursement align with execution.
For sector peers working on TTFields or other high-innovation oncology modalities, this report reinforces the importance of a multi-market push and the leverage of regulatory milestones in de-risking long-run adoption. Expect analysts to test whether operating leverage can emerge as patient volumes rise, particularly if the pipeline across indications and geographies matures faster than anticipated.
Outlook and takeaways
Management’s tone—emphasizing “well-positioned to advance our patient-forward mission while driving sustainable growth and making material progress on our path to profitability”—frames the near-term narrative as one of continued revenue expansion tempered by ongoing investment. Even without a formal revenue forecast disclosed in this release, the quarterly performance sets a benchmark for how NVCR could navigate next steps: expand regulatory approvals where feasible, push payer access, and convert patient growth into more meaningful operating leverage.
In the broader oncology devices space, NVCR’s mix shifts and international expansion plans could influence peers, particularly those pursuing cross-border launches or collaborations with regional biopharma players. The key questions for the sector remain: will patient access improve fast enough to sustain revenue growth, and can the company translate that into a clearer path to profitability—whether via higher gross margins, cost discipline, or a combination of both?
Bottom line
NVCR delivered a quarter that underscores the tension between record revenue and the journey to sustained profitability. For investors tracking earnings metrics like EPS, earnings surprise potential, and revenue forecast revisions, the results provide fodder for a cautious-but-optimistic read on TTFields’ expansion upside and the sustainability of margins as the company climbs new regulatory and commercial ladders.